Position in GPCR
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$6,095,420
New position
Shares Held
126,461
first reported quarter
Ownership
0.059%
of shares outstanding
% of Portfolio
1.67%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 7%
Shared 0%
None 93%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Davern Capital Partners, LP holds $259,367,571 across 13 Biotechnology names. GPCR ranks #12 (2.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
44,800 | $34,614,272 | |
| 2 | INSM |
INSMED Inc
|
182,562 | $29,852,538 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
386,903 | $29,052,546 | |
| 4 | BNTX |
BioNTech SE
|
305,055 | $27,113,288 | |
| 5 | ARGX |
Argenx SE
|
35,045 | $25,591,611 | |
| 6 | RPRX |
Royalty Pharma plc
|
520,009 | $24,944,831 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
873,398 | $24,193,124 | |
| 8 | LEGN |
Legend Biotech Corp
|
1,314,748 | $23,783,791 |
All Filings in GPCR
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,095,420 | 126,461 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||